pleiotropy

(redirected from pleiotropic)
Also found in: Medical, Encyclopedia.
Related to pleiotropic: Pleiotropic Genes

plei·ot·ro·py

 (plī-ŏt′rə-pē) also plei·ot·ro·pism (-pĭz′əm)
n. Biology
The production of diverse effects, especially the production by a single gene of several distinct and seemingly unrelated phenotypic effects.

[Greek pleiōn, more; see pelə- in Indo-European roots + -tropism.]

plei′o·tro′pic (plī′ə-trō′pĭk, -trŏp′ĭk) adj.

plei•ot•ro•py

(plaɪˈɒ trə pi)

n.
the phenomenon of one gene affecting more than one phenotypic characteristic.
[1935–40]
plei`o•trop′ic (-əˈtrɒp ɪk, -ˈtroʊ pɪk) adj.
plei`o•trop′i•cal•ly, adv.
Mentioned in ?
References in periodicals archive ?
Use of Statins: Statins have not only effects on lipids but have pleiotropic effects like anti-inflammatory, anti-oxidants, anti-thrombotic and cardio-metabolic effects.
Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Pleiotropic actions of peroxisome proliferator activated receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives.
Mutations at the KIT locus can lead to pleiotropic developmental defects in pigment cells, and KIT activation impacts blood cells (Geissler et al.
Regarding the shared familial factors, I'm tempted to hypothesize that this might involve pleiotropic effects reflecting genetic variants associated with impulsivity," said Dr.
Rather, the strong implication is that the explanation for the observed preventive effect lies in the pleiotropic effects of the statin therapy routinely prescribed in accordance with guidelines once women received the diagnosis of hyperlipidemia, he continued.
Interleukin 21 (IL-21) has a pleiotropic effect on inflammation regulation.
The appointment of Dunsire as president and chief executive officer occurs at a time when XTuit's pipeline of microenvironment-targeted drug candidates is advancing toward clinical development, with the ability to act through pleiotropic mechanisms to address multiple pathways that cause the disease-promoting microenvironment.
MSC-1 is a first-in-class antibody that targets leukemia inhibitory factor, a pleiotropic cytokine that is overexpressed in certain solid tumors.
Metformin is a biguanide derivate and has pleiotropic effects (1).
Cell-based therapy is distinguished from small molecule strategies by the pleiotropic mechanisms of action that have been determined in preclinical data and an excellent safety profile in early clinical trials.